Based on these findings, it is interesting to speculate that perhaps FDA-approved C3 inhibitors (for geographic atrophy) such as Pegcetacoplan (SYFOVRE) [118] may ultimately be repurposed for use in ML/DHRD, possibly with better functional outcomes than has occurred in dry AMD. The gene discussed is C3; the disease is atrophic macular degeneration.